Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | PHASE1 | RECRUITING | 80 | — | — | Apr 1, 2019 | Jul 1, 2027 | Feb 25, 2025 | 1 | China |
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of BCMA CAR-T treatment will be recorded and assessed according to the IMWG
| Arm | Type | Description |
|---|---|---|
| BCMA CAR-T cells treat | EXPERIMENTAL | Patients will be be treated with BCMA CAR-T cells |
| Name | Type | Description |
|---|---|---|
| BCMA CAR-T cells | BIOLOGICAL | BCMA CAR-T cell therapy |
Inclusion Criteria: 1. Signed written informed consent; 2. Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory...